Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score –Matched Analysis from the Korean College of Rheumatology Biologics Registry

ConclusionsPropensity score –matching analysis confirmed that CT-P13 treatment was not associated with significant differences in drug retention, treatment duration, most efficacy parameters, or safety versus reference infliximab in Korean patients with ankylosing spondylitis, building evidence for the long-term comparabilit y of these treatments.Trial registrationClinicalTrials.gov identifier: NCT01965132.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research